Search
Fosun Pharma: Subsidiary Secures FDA Approval for Phase I Clinical Trial of HLX43 Injection
2025-08-07 /
Read about 0 minute
Author：小编
Fosun Pharma's subsidiary, Henlius Biotech, has garnered approval from the US Food and Drug Administration (FDA) to embark on Phase I clinical trials for HLX43 injection, a promising treatment for thymoma. HLX43, an antibody-drug conjugate specifically targeting PD-L1, is tailored to combat advanced or metastatic solid tumors. Henlius Biotech intends to initiate global, multicenter clinical studies in Australia, Japan, the United States, and other regions once conditions are favorable. As of June 2025, the company has invested approximately RMB 182 million in the research and development of this groundbreaking drug.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
